GleamWall
中文EN

LSTA LISATA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 320017 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-90.7%
TTM net income YoY5.9%
TTM EPS YoY11.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-22,043.0%
Net margin-17,159.0%
FCF margin-21,662.0%
EBITDA margin-22,020.0%

Returns

ROE-137.2%
ROA-5.1%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets8.8%
Debt / equity0.00x
Current ratio14.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio1.3%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312024Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$100,000$0$70,000$0$1.00M
R&D expense$5.21M$584,000$1.20M$1.13M$1.96M$2.25M$2.60M$2.95M
SG&A expense$4.82M$3.41M$3.74M$2.04M$2.46M$2.69M$3.25M$3.00M
Operating income-$10.03M-$3.99M-$4.94M-$3.08M-$4.41M-$4.87M-$5.85M-$4.95M
Pretax income-$12.81M-$2.93M-$4.88M-$2.95M-$4.25M-$4.66M-$5.69M-$4.61M
Income tax-$6.03M$0-$387,000$0$0$0-$962,000$0
Net income-$6.79M-$2.93M-$4.49M-$2.95M-$4.25M-$4.66M-$4.72M-$4.61M
EBITDA-$10.03M-$3.99M-$4.94M-$3.06M-$4.37M-$4.82M-$5.80M-$4.91M
EPS (basic)-0.73-0.32-0.50—-0.49-0.54-0.55—
EPS (diluted)-0.73-0.32-0.50—-0.49-0.54-0.55—
Weighted avg. shares (diluted)9.30M9.11M9.01M—8.74M8.61M8.60M—
Balance sheet
Cash & equivalents$282.72M$10.44M$13.06M$15.96M$19.00M$16.84M$20.22M$16.21M
Receivables———$0———$900,000
Current assets$287.75M$11.01M$14.02M$17.70M$21.57M$24.89M$28.62M$34.58M
PP&E, net$177,000$14,000$16,000$18,000$22,000$48,000$74,000$72,000
Goodwill$64.73M——$0————
Intangibles$292.90M$400,000$400,000$0$400,000$400,000$400,000$192,000
Total assets$648.41M$11.03M$14.06M$17.74M$21.76M$25.16M$28.98M$35.00M
Current liabilities$20.42M$2.99M$3.31M$3.07M$4.57M$4.31M$3.81M$5.61M
Total liabilities$56.77M$3.04M$3.39M$3.14M$4.64M$4.38M$3.88M$5.68M
Shareholders' equity$7.64M$8.24M$10.93M$14.86M$17.37M$21.03M$25.36M$29.57M
Shares outstanding10.80M9.12M9.11M8.83M8.76M8.63M8.62M8.41M
Cash flow statement
Operating cash flow-$12.68M-$2.65M-$3.08M-$3.25M-$3.34M-$3.96M-$5.40M-$4.53M
Capital expenditure$0$0$0$0$0$0$28,000$0
Free cash flow-$12.68M-$2.65M-$3.08M-$3.25M-$3.34M-$3.96M-$5.43M-$4.53M
Investing cash flow$72.92M$0$0$0$5.15M$505,000$9.43M$1.39M
Financing cash flow$212.06M$29,000$181,000$205,000$353,000$64,000-$23,000-$96,000
Depreciation & amortization$3,000$3,000$2,000$15,000$44,000$44,000$43,000$41,000
Stock-based compensation$58,000$214,000$364,000$225,000$232,000$239,000$530,000$635,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.